EUVIMEDEUVIMED entdecken
Scoping ReviewRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review

Sophie Cooling, Yvonne Ann Bonomo, David Castle, Christine Mary Hallinan

Clinical Drug Investigation · 2026

DOI: 10.1007/s40261-025-01501-3 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Clinical Drug Investigation, 2026. Verfasst von Sophie Cooling und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Practice and Primary Care, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, Medical Building, The …. Hauptthemen laut MEDLINE: Medical Marijuana, Mental Disorders, Substance-Related Disorders. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: With shifting perceptions about the therapeutic potential of cannabis and evolving regulatory frameworks, global prescribing of medicinal cannabis is increasing. While some emerging evidence supports its use for conditions like multiple sclerosis and epilepsy, its efficacy and safety profile for the treatment of mental health conditions remains controversial and under-explored. Previous reviews found inconclusive evidence due to heterogeneity in study design and quality. Accordingly, this review was designed as a scoping review, consistent with established methodological frameworks to map and characterise all available randomised controlled trial (RCT) evidence in this emerging and heterogeneous field. It specifically sought to synthesise the highest-quality trial evidence to date, addressing the question: How effective is medicinal cannabis in treating mental health conditions, as classified by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and how safe and tolerable is it, as assessed through adverse events and treatment withdrawals? METHODS: A scoping review was conducted comprising RCTs investigating medicinal cannabis for mental health conditions. Eligible studies were required to meet predefined inclusion criteria based on population, intervention, comparator, outcomes, and study design (PICOS framework). PubMed, Web of Science, and PsycINFO databases were searched, supplemented by citation tracking and Google Scholar, for studies published between 1980 and 2024. RESULTS: The search identified 8061 studies, with 28 RCTs meeting inclusion criteria across 12 DSM-5 mental health conditions. Indications most frequently studied were schizophrenia (n = 5), cannabis use disorder (n = 4), cocaine use disorder (n = 4), post-traumatic stress disorder (n = 3), anxiety disorders (n = 3), and opioid use disorder (n = 2); there were two trials in autism spectrum disorder and single trials in depression, attention-deficit/hyperactivity disorder, obsessive-compulsive disorder, tobacco use disorder, and Tourette syndrome. Sample sizes ranged from 6 to 150 participants (median = 42), and follow-up durations from 1 day to 13 weeks (median = 6 weeks). Interventions included purified cannabidiol (CBD; single doses of 300-800 mg and daily regimens up to 1000 mg/day), nabiximols or other tetrahydrocannabinol (THC)/CBD oromucosal sprays (up to 113 mg THC/105 mg CBD per day), and smoked or vaporised cannabis flower of varying THC/CBD content. Findings showed substantial heterogeneity and variable quality, with some short-term benefits reported (notably in cannabis use disorder, autism spectrum disorder, and schizophrenia), but no trial demonstrated long-term efficacy. CONCLUSION: Despite growing interest, substantial heterogeneity limits current evidence for medicinal cannabis in mental health. This review highlights key gaps, underscoring the need for robust, well-powered RCTs with extended follow-up to clarify its role in the management of mental ill health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medical MarijuanaMental DisordersSubstance-Related DisordersHumansRandomized Controlled Trials as TopicMental Health

Substanzen

Medical Marijuana

Autor:innen und Institutionen

  • Department of General Practice and Primary Care, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, Medical Building, The University of Melbourne, 181 Grattan Street, Parkville, VIC, 3010, Aus…
  • Department of Addiction Medicine, St Vincent's Hospital Melbourne, Fitzroy, Australia, 3065, VIC.
  • Women's Alcohol and Drug Service, The Royal Women's Hospital, Parkville, Australia, 3050, VIC.
  • Department of Medicine, The University of Melbourne, Parkville, Australia, 3010, VIC.
  • Centre for Mental Health Service Innovation and University of Tasmania, Hobart, TAS, Australia, 7005.
  • Department of Addiction Medicine, St Vincent's Hospital Melbourne, Fitzroy, Australia, 3065, VIC. hallinan@unimelb.edu.au.

Zitieren

APA

Cooling, S., Bonomo, Y. A., Castle, D., & Hallinan, C. M. (2026). Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01501-3

Vancouver

Cooling S, Bonomo YA, Castle D, Hallinan CM. Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review. Clinical Drug Investigation. 2026. doi:10.1007/s40261-025-01501-3

BibTeX
@article{Cooling2026,
  author = {Cooling, Sophie and Bonomo, Yvonne Ann and Castle, David and Hallinan, Christine Mary},
  title = {Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review},
  journal = {Clinical Drug Investigation},
  year = {2026},
  doi = {10.1007/s40261-025-01501-3}
}
Kostenlos starten →